SUCCESS IN CNS DRUG DEVELOPMENT – INNOVATION IN RARE DISEASES

Stefan Weber, CEO
Jefferies 2019 Healthcare Conference, New York City
June 7, 2019
Disclaimer

RESTRICTED SCOPE; EXCLUSION OF LIABILITY; CONFIDENTIALITY

This document has been prepared by Newron Pharmaceuticals S.p.A. ("Newron") solely for your information. The information contained herein has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Newron does not undertake any obligation to update or revise any information contained in this presentation. None of Newron, its advisors or any of their respective representatives or affiliates shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document.

None of Jefferies International Limited ("Jefferies"), Kempen & Co N.V. ("Kempen") or Kepler Cheuvreux S.A. ("Kepler") or any of their respective directors, officers, employees, advisers and agents accept any responsibility or liability whatsoever for/or makes any representation or warranty, express or implied, as to the truth, fullness, accuracy or completeness of the information in this document (or whether any information has been omitted from the document) or any other information relating to Newron or its associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

None of Newron, Jefferies, Kempen, Kepler or any of their respective directors, officers, employees, agents, affiliates or advisers is under any obligation to update, complete, revise or keep current the information contained in this document to which it relates or to provide the recipient of with access to any additional information that may arise in connection with it. Jefferies, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Newron and no one else in connection with this document or any future transaction in connection with it. Jefferies will not regard any other person (whether or not a recipient of this document) as a client or will be responsible to anyone other than Newron for providing the protections afforded to its clients or for the giving of advice in relation to the contents of this document or any transaction, matter or arrangement referred to in this document.

This copy of the presentation is strictly confidential and personal to the recipient. It may not be (i) used for any purpose other than in connection with the purpose of this presentation, (ii) reproduced or published, (iii) circulated to any person other than to whom it has been provided at this presentation.

FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. Statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.

By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.

NO OFFER OR INVITATION; NO PROSPECTUS

This document does not constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document is not a prospectus within the meaning of art. 652a of the Swiss Code of Obligations or article 32 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (3) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order, or (4) qualified investors, pursuant to article 100 of Legislative decree 58/98, as amended (all such persons in (1) to (4) above together being referred to as “relevant persons”). Any person who is not a relevant person should not act or rely on this document or any of its contents.

ACCEPTANCE OF DISCLAIMER

By accepting this document, you acknowledge and agree to each of the foregoing disclaimer.
Company Highlights

Diversified portfolio of innovative CNS product candidates
- Xadago® for Parkinson’s disease – validation of Newron’s development approach – from research to market
- Sarizotan for Rett syndrome – in late Phase III development
- Evenamide – Re-defining the treatment of poor/non-response in schizophrenia

Significant near-term value drivers

Management team with proven track record

Fully funded beyond key value inflexion points
- Cash balance of about € 44m (December 31, 2018)
- Access to long term loan facility of up to € 40m (European Investment Bank)
Successful Track Record in CNS Product Development

**Xadago® (safinamide)**
Commercialized by partner in 15 European markets and the US for Parkinson’s disease (“PD”)
- Newron receives milestone and royalty payments from sales of safinamide in PD
  - €40m received to date

**Sarizotan**
Close to completion of Phase III program in Rett syndrome (orphan disease)
- Newron will commercialize Sarizotan for Rett syndrome in the US and – if viable – in key EU territories

**Evenamide (NW-3509)**
Phase IIa trial demonstrated PoC
- Ready for Phase III program in two indications. Opportunities for commercialization by Newron (Clozapine TRS population) and partnering (major indication)
**Innovative Clinical Pipeline with Multiple Near-Term Catalysts**

<table>
<thead>
<tr>
<th>PRODUCTS</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Market</th>
<th>Commercial Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Xadago® (safinamide)</strong></td>
<td>Adjunctive therapy in PD</td>
<td>Adjunctive therapy in PD</td>
<td>Adjunctive therapy in PD</td>
<td>Levodopa Induced Dyskinesia (PD LID)</td>
<td>Zambon</td>
</tr>
<tr>
<td><strong>Sarizotan</strong>²</td>
<td>Rett syndrome (Orphan drug status)</td>
<td></td>
<td></td>
<td></td>
<td>Newron</td>
</tr>
<tr>
<td>**Evenamide (NW-3509)**¹</td>
<td>Adjunctive therapy in Schizophrenia</td>
<td>Adjunctive therapy in Clozapine TRS</td>
<td></td>
<td></td>
<td>Newron</td>
</tr>
<tr>
<td><strong>Ralfinamide</strong>¹</td>
<td>Orphan indication in neuropathic pain</td>
<td></td>
<td></td>
<td></td>
<td>Newron</td>
</tr>
</tbody>
</table>

**Expected Milestones**

- **Xadago®:** Further launches expected Study in patients with Levodopa Induced Dyskinesia (PD LID) expected to start HY I 2019
- **Sarizotan:** Potentially pivotal study commenced; results expected QIV 2019; own commercialization
- **Evenamide:** Potentially pivotal studies expected to start in 2020

**Ongoing search for strategically relevant assets to in-license**

---

¹ Safinamide, Evenamide and Ralfinamide all developed from Newron's ion channel based research
² Sarizotan was licensed from Merck KGaA
Xadago®: 1st New Chemical Entity Approved in a Decade for Parkinson's Disease

A progressing disorder, no cure available yet

- 2nd most common chronic progressive neurodegenerative disorder in the elderly
- Affecting 1-2% of individuals aged ≥ 65 years worldwide
  - 20% to 30% in early stage
  - 70% to 80% percent in mid to late stage
  - >$4 billion worldwide market

Fast and sustained efficacy, well tolerated

MID- TO LATE-STAGE PD PATIENTS – add-on to L-Dopa dopamine replacement

- Significant improvement of
  - ON Time/OFF Time – regulatory endpoint
  - UPDRS II – activities of daily living
  - UPDRS III – motor function
  - CGI (clinical global impression) – severity and improvement
- Additional ON Time without any increase in any dyskinesia
Xadago®: New Label Study in Patients with Levodopa Induced Dyskinesia

- Newron and partner Zambon have completed designing a potentially pivotal study to evaluate Xadago® in patients with levodopa induced dyskinesia (PD LID).
- Study to be performed in Europe and US.
- Supportive evidence of Xadago’s anti-dyskinetic effect:
  - Mechanism, i.e. glutamate release inhibition
  - LID models
  - PD patient data: significant benefit on DRS (Dyskinesia Rating Scale) in 223 dyskinetic PD patients in a 2 year-placebo-controlled study.
- Study design agreed upon with FDA.
- Study expected to start in 2019.
**Significant Commercial Opportunity in Xadago® (Safinamide)**

- **US / Canada**
  - Launched in US in July 2017
  - Regulatory approval for Canada

- **EU**
  - Launched in Germany, UK, Italy, Spain and other EU territories, and Switzerland; regulatory approval for Brazil and Colombia, application for regulatory approval filed for Mexico

- **Latin America**
  - Application for regulatory approval filed

- **Israel**
  - Phase II/III completed in Jan. 18; application for regulatory approval filed

- **Japan / Asia**
  - Regulatory approval for Australia

- **Australia / New Zealand**

» Parkinson’s disease affects 7 to 10 million people worldwide

» Milestone and royalty revenues to Newron since 2012

» Long period of Xadago® market exclusivity (patent life: 2029 in EU, 2031 in the US)
Rett Syndrome: A Severe Neuro-Development Orphan Disease

Spontaneous mutations in the X-linked MeCP2 gene

- Disease manifests almost exclusively in females with one affected X-chromosome
- Normal development until 6-18 months of age, then loss of skills and ability for social interaction
- Respiratory abnormalities, motor and severe intellectual impairment, sleep abnormalities and seizures in most patients (70-90%)

25% of sudden deaths in Rett syndrome may be due to cardio-respiratory abnormalities

- Estimated 36,000 patients in US and EU combined
- Focus on symptom management

No Approved Treatment Options
Sarizotan: Targeting Respiratory Disturbances in Rett Syndrome Patients

- First Rett syndrome drug candidate targeting respiratory disturbances as primary efficacy outcome
- Deficits in serotonergic transmission due to the MeCP2 mutation in the mid-brain nucleus underlie the respiratory abnormalities in MeCP2 deficit mice
- Sarizotan, a full agonist at the serotonergic 5HT1A receptor, has demonstrated dramatic improvement of respiration in genetic (MeCP2) mouse model of RTT
- Development path/regulatory requirements for approval agreed upon with FDA/EMA/HPB
- Orphan drug designation in EU and US

EFFECTS OF ACUTE ADMINISTRATION WITH SARIZOTAN IN RETT FEMALE MICE (MECP2R168X/+). BENEFIT PERSISTS IN LONG LASTING TREATMENTS (14-DAYS-MECP2R168X/+)

Apnea in MeCP2-deficient mice

Apnea in MeCP2-deficient mice treated with Sarizotan 5.0 mg/kg

STARS: First Ever Global Phase III Study in Rett Syndrome

- Protocol/program discussed and approved by HA in UK, Germany, Sweden, Spain, Canada, CHMP, and US
- Randomized, double-blind, placebo-controlled, six-month study evaluating efficacy and safety of sarizotan in at least 129 Rett syndrome patients with respiratory symptoms
  - Females and males ≥ 4 years, body weight ≥ 10 kg meeting RTT consensus clinical criteria, confirmed by MECP2 mutations
  - Patients meet all criteria related to breathing abnormalities:
    - ≥10% of the time with abnormal breathing
    - At least 10 episodes of breathing dysrhythmia (≥10 seconds of breath holding, apnea)/hour during cardiorespiratory monitoring (home/ambulatory monitoring system - BioRadio™)
- 14 Centers of excellence in the United States, Italy, UK, Australia and India
- Primary endpoint:
  - Percent reduction in number of apnea episodes/hour
    - Primary efficacy variable to be calculated from data from home cardiorespiratory monitoring
    - Measurements to be performed for 6-hr per day, during time awake, on any 3 days during the week
    - Weeks 2, 8, 16 and 24
- Enrollment completed
- Results expected QIV 2019
The natural history study points to the fact that respiratory symptoms start early in these patients (minimum 0.7 years: median 3 years), quickly become prominent and dramatic, but wane over time; they are correlated with worsening of the core symptoms and with Long QTc interval.

- but there has been no systematic attempts to quantitate these breathing abnormalities, their time course, the associated effects on SpO2 saturation.

- STARS data suggest that the proportion of patients with respiratory abnormalities does not decline with age.

- Quantitative recordings for over 18 hours in the home setting indicate that up to 70% of patients evaluated experience clinical significant apnea.

- Oxygen saturation goes below 90% 4.2 times per hr, duration may last a long as 48 minutes/hr.

- Definitive data will be available late next year, however anecdotal data from investigators suggest that greater awareness of surroundings, increased attempt at non-verbal communication, greater alertness noted in patients who experience some improvement in apnea’
Sarizotan Market Opportunity and Commercialization Strategy

Initiation of a Health Economic Outcome Research Study (HEOR) → “burden of illness”
- Partnerships and collaborations with Rett advocacy, thought leaders & governing payers
- Global survey to quantify the ways in which patient “respiratory breathing abnormalities” affect daily life
- Meets Health Technology Assessment (HTA) requirements
- International Experts advocated timely approach as critical for management of patients

Goals
- Align economic & clinical outcomes
- Create awareness to breathing abnormality burden
- Optimize market uptake, access, reimbursement
- Build Newron leadership

Rare Pediatric Disease Priority Review Voucher Program

US 16,000 patients
Orphan exclusivity
7.5 years post approval

EU 20,000 patients
Orphan exclusivity
12 years post approval

Small team ~ 25-30 medical liaison managers required to commercialize sarizotan in US and Europe
Schizophrenia: No Effective Treatment that Reduces Burden of Disease in Last 20 Years

- **VAST MARKET OPPORTUNITY**
  - (anti-psychotics market >$23bn)

Globally over 4 million patients
- Disease onset in 20s, need for life long treatment
- Cost to society (direct cost US only): $63bn p.a.

**Efficacy of current treatment options is insufficient**

Onset of disease occurs in early adulthood affecting 1% of the population worldwide
- Efficacy of typicals and atypicals limited and wanes over 18 months; severe side effects; 64-82% of patients switch but without additional benefits
- Treatment-resistant schizophrenia (TRS)
  - Min. 30% of patients after 3-5 years are TRS: only clozapine shows efficacy
  - 30-50% of these patients show resistance to clozapine; no therapeutic option left
- Outcomes for 1-year treated young US first episode patients: 24 times greater mortality than age matched (16-30 year olds) controls despite use of antipsychotics (40%) and mental health services (Schoenbaum, 2017)
Evenamide Novel MoA: Synergistic with Marketed Antipsychotics

- Evenamide, a Voltage-Gated Sodium Channels (VGSC) blocker has the potential to target the abnormal neuronal activity and glutamate transmission in patients with schizophrenia
- Evenamide may add to or synergize with antipsychotic drugs to bring about a combined therapeutic effect on glutamate and dopamine systems
  - Effects seen in combination with haloperidol, risperidone and aripiprazole
- Composition of matter – USPTO, 2013 – patent life 2028 plus extension

Voltage-Gated Sodium Channels (VGSC) blockers may act synergistically with antipsychotics in schizophrenia therapy

Dysregulation of mesolimbic and mesocortical dopamine system
Normalization of the dopaminergic transmission in the mesolimbic system

Dysregulation of cortical neuronal activity and glutamate transmission
Decrease of excessive glutamate tone by reducing abnormal firing activity

Psychosis and cognitive impairment

Adapted from Lange et al (Psychopharmacology 2003, 181:415-436)
Evenamide is Active in a Wide Range of Schizophrenia and Psychiatric Animal Models as a Monotherapy and as an Add-on to Existing Antipsychotics

<table>
<thead>
<tr>
<th>Information Processing Deficit</th>
<th>Monotherapy</th>
<th>Add-on</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-pulse inhibition (PPI) disrupted by dopamine activation (amphetamine -rat)</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-pulse inhibition (PPI) disrupted by NMDA antagonists (MK-801, PCP, -rat)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Pre-pulse inhibition (PPI) disrupted by natural stimuli (sleep deprivation -rat)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Pre-pulse inhibition spontaneous deficit (C57 mice)</td>
<td>✓*</td>
<td>✓</td>
</tr>
<tr>
<td>Pre-pulse inhibition (PPI) disrupted by Ketamine in rat</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Negative Symptoms</th>
<th>Monotherapy</th>
<th>Add-on</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCP-induced deficit in Social Interaction in the rat</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Saccharin preference test (anhedonia) in prenatal poly:IC exposed mice <em>(ongoing)</em></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Three-chamber sociability test in prenatal poly:IC exposed mice <em>(ongoing)</em></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Forced swimming test (avolition) in prenatal poly:IC exposed mice <em>(ongoing)</em></td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Psychosis and Mania</th>
<th>Monotherapy</th>
<th>Add-on</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamine induced hyperactivity in mice</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Amphetamine plus Chlordiazepoxide induced hyperactivity in mice</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cognitive Impairment</th>
<th>Monotherapy</th>
<th>Add-on</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novel object recognition in the rat: short term scopolamine impairment</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Novel object recognition in the rat: long term 24 hr natural forgetting</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Impulse Control and Mood Symptoms</th>
<th>Monotherapy</th>
<th>Add-on</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resident–Intruder test in mice (Impulsivity)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Tail suspension test in mice (Depression)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Marble burying test in mice (Obsessive Compulsive Disorders)</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

*Trend<br><br>Blank cells = not evaluated
Evenamide: PoC in Patients with Schizophrenia Demonstrated

- 4-week, placebo-controlled, add-on study of evenamide (15-25mg BID/day) in 89 patients on stable doses of aripiprazole or risperidone showing signs of worsening when compared to standard of care, at every assessment during the study (starting day 8)

  - **Significant improvement of**
    - PANSS positive, both mean change AND responder rate
    - CGI-C

  - **Superior benefit on**
    - PANSS total
    - LOF total
    - CGI-S

- Glutamatergic MoA seems to improve symptoms of psychosis in patients not responding to D2/5HT2 blockade
EVENAMIDE: REGULATORY INTERACTIONS AND PHASE III CLINICAL DEVELOPMENT PLAN

All Health Authorities (Spain, Denmark, Sweden, Germany, UK, CHMP, US, Canada) in agreement with proposed Phase III plan

Newron expects new explanatory studies requested by health authority to be completed, allowing Phase III start in 2020

Efficacy program will be comprised of two pivotal studies in specific populations:

- **Non-treatment resistant patients**: chronic schizophrenics experiencing inadequate benefit for symptoms of their psychosis, on current atypical antipsychotic monotherapy (risperidone, aripiprazole, paliperidone, olanzapine, or quetiapine) – **Planned Study 003**
- **Treatment resistant schizophrenia**: Patients whose psychotic symptoms are not responding adequately to treatment with clozapine - **Planned Study 004**

Positive results of both studies would meet efficacy criteria for both indications
Positive result of study 004 only would lead to approval of clozapine-resistant population only
Positive result of study 003 only would lead to need for another similarly designed study
Start of Phase III program expected 2020 – appr. 18 months to results
Company Highlights

Diversified portfolio of innovative CNS product candidates
  • Xadago® for Parkinson’s disease – validation of Newron’s development approach – from research to market
  • Sarizotan for Rett syndrome – in late Phase III development
  • Evenamidine – Re-defining the treatment of poor/non-response in schizophrenia

Significant near-term value drivers

Management team with proven track record

Fully funded beyond key value inflexion points
  • Cash balance of about € 44m (December 31, 2018)
  • Access to long term loan facility of up to € 40m (European Investment Bank)
CONTACT DETAILS

NEWRON
STEFAN WEBER – CEO
+39 02 6103 46 26
pr@newron.com

UK/EUROPE
JULIA PHILLIPS / NATALIE GARLAND-COLLINS, FTI CONSULTING
+44 20 3727 1000
scnewron@fticonsulting.com

SWITZERLAND
MARTIN MEIER-PFISTER, IRF REPUTATION AG
+41 43 244 81 40
meier-pfister@irf-reputation.ch

GERMANY/EUROPE
ANNE HENNECKE, MC SERVICES
+49 211 52925222
anne.hennecke@mc-services.eu

USA
PAUL SAGAN, LAVOIEHEALTHSCIENCE
+1 617 374 8800, EXT. 112
psagan@lavoiehealthscience.com